In terms of safety, all 39 patients were evaluable and the agent was well-tolerated overall, with most treatment-emergent adverse events (TEAEs) being grade 1 or 2. Occurring in more than 25% of the study population, the most common TEAEs of any grade were dizziness (62%), fatigue (39%), constipation (33%), dysgeusia (33%), and dyspnea (28%). No grade 3 dizziness or dizziness leading to treatment discontinuation was observed in the study.